EZH2 plays a pivotal role in supporting NE differentiation and EMT, both of which contribute to tumor progression and resistance mechanisms.54,73–76 A recent clinical study showed that combining mevrometostat, an EZH2 inhibitor, with enzalutamide improved progression-free survival and response rates in metastatic CRPC compared to enzalutamide alone.77 FOXA1, a pioneer transcription factor, facilitates chromatin remodeling and regulates AR-dependent transcription. This evidence concerns the gene EZH2 and neoplasm.